SIOG 2022 ADVANCED COURSE IN GERIATRIC ONCOLOGY CANBERRA PROGRAMME
<table>
<thead>
<tr>
<th>CONTENTS</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome Address</td>
<td>3</td>
</tr>
<tr>
<td>About SIOG</td>
<td>3</td>
</tr>
<tr>
<td>• SIOG Board Members</td>
<td>4</td>
</tr>
<tr>
<td>• SIOG National Representatives Committee</td>
<td>4</td>
</tr>
<tr>
<td>• SIOG Membership</td>
<td>4</td>
</tr>
<tr>
<td>Scientific &amp; Educational Projects</td>
<td>6</td>
</tr>
<tr>
<td>• SIOG Task Forces</td>
<td>6</td>
</tr>
<tr>
<td>• E-Learning Modules</td>
<td>6</td>
</tr>
<tr>
<td>• SIOG Preceptorship</td>
<td>6</td>
</tr>
<tr>
<td>SIOG Advanced Course in Geriatric Oncology - Scientific Committee</td>
<td>7</td>
</tr>
<tr>
<td>Accreditation</td>
<td>7</td>
</tr>
<tr>
<td>Speakers</td>
<td>8-11</td>
</tr>
<tr>
<td>Scientific Programme</td>
<td>12-13</td>
</tr>
<tr>
<td>Industry Symposium</td>
<td>14</td>
</tr>
<tr>
<td>Sponsors</td>
<td>15</td>
</tr>
<tr>
<td>Supporting Organisation</td>
<td>16</td>
</tr>
<tr>
<td>Acknowledgement</td>
<td>17</td>
</tr>
</tbody>
</table>
WELCOME ADDRESS

It is with pleasure that we hold the second virtual edition of the SIOG Advanced Course in Geriatric Oncology from Canberra, Australia. We have an exciting programme, welcoming members both new and existing – to reflect upon, renew friendships and extend our networks, and jointly explore current and future research directions in Geriatric Oncology.

The Course is designed for professionals who want to stay at the peak of their expertise for the treatment and care of older cancer patients. It is delivered by international and local experts and is designed by the SIOG Faculty to provide specific skills in assessment, care pathways and therapeutic choices for older patients with cancer.

The different themes and topics will cover the general principles of cancer treatment using case-based discussions. As with our other SIOG Advanced Courses, this edition will be a unique opportunity to forge greater collaboration and partnerships. We strive to enable as many professionals as possible to benefit from this exchange.

We hope that you will have a productive and fun-filled time at this course.

Dr Divyanshu Dua
Chair, SIOG 2022 Advanced Course – Canberra
National Convener

ABOUT SIOG

The International Society of Geriatric Oncology, also called SIOG (Société Internationale d’Oncologie Gériatrique) in French, is a multidisciplinary membership-based society with members engaged in more than 80 countries around the world. Our network includes geriatricians, medical oncologists, surgical oncologists, radiation oncologists, anaesthesiologists, nurses and allied health professionals. Founded in 2000, SIOG was officially registered as a not-for-profit organisation under the Swiss law in October 2012. Ever since, SIOG has established a long-standing history of implementing programmatic activities in the field of Geriatric Oncology via 3 strategic directions: education, clinical practice and research.

Powered by global collaborations, the SIOG network is committed to strengthening the national capacity for Human Resources for Health (HRH) in various countries and in promoting and advocating for the health agenda of the Sustainable Development Goal (SDG3) i.e. ‘Ensure healthy lives and promote wellbeing for all at all ages’.

MISSION & VISION

The goal of SIOG is to strengthen the capacity of health professionals in the field of geriatric oncology, in order to optimise treatment of older adults with cancer.

SIOG operates via 3 strategic directions:

EDUCATION
- Disseminate knowledge in order to maintain a high common standard of healthcare in older cancer patients.
- Integrate geriatric oncology in the curricula for medical and nursing education to ensure a high standard of qualification for healthcare professionals.
- Address the shortage of specialist oncologists/geriatricians & allied health staff in geriatric oncology.
- Increase public awareness of the worldwide cancer in the elderly epidemic.

CLINICAL PRACTICE
- Integrate geriatric evaluation (including comorbidities) into oncology decision-making and guidelines.
- Improve the quality of prevention, diagnosis, treatment, and follow-up of older patients with malignancies.
- Address issues of access to care, including the needs of the caregiver.
- Develop interdisciplinary geriatric oncology clinics.

RESEARCH
- Develop, test and disseminate easy screening tools.
- Create a clear and operational definition of vulnerability/frailty applicable to oncology.
- Increase the relevance of clinical trials for older patients.
- Improve research in the field of geriatric oncology.
- Promote multidisciplinary basic/translational research on the interface of ageing and cancer.
SIOG BOARD

SIOG NATIONAL REPRESENTATIVES COMMITTEE

The SIOG National Representatives (NRs) Committee is one of strategic bodies of SIOG, with an important role in linking SIOG’s core with members, institutions and experts around the globe.

As SIOG spokespersons in their respective countries, our National Representatives act as ambassadors of SIOG’s mission, sharing the same values and pursuing the same objectives, in the joint effort to promote progress and innovation in geriatric oncology. They work closely with the SIOG head office to handle various topics of importance at the local and international level. The members of the SIOG NR play a critical role in ensuring that the national priorities are respected, that SIOG’s activities stimulates human resource development with the respective national contexts.

With guidance from the member of the SIOG NR on the design, facilitations and evaluation of its activities and impact, SIOG ensures an integrative approach in the implementation of its activities worldwide.

SIOG MEMBERSHIP

SIOG members share a passion to bring good clinical practices in the elderly. Current SIOG membership comprises over 2000 individual members in 80 countries and continues to grow. Our current members include scientists, surgical oncologists, geriatricians, medical oncologists, radiation oncologists, psychologists, sociologists, nurses, nurse practitioners, and other healthcare professionals active in the area of clinical practice interested in and/or involved in the management of older patients with cancer. Currently, SIOG offers two types of membership: Individual and Society.

INDIVIDUAL MEMBERSHIP BENEFITS

- Submit articles to the Journal of Geriatric Oncology (JGO), the leading journal specifically dedicated to geriatric oncology;
- Access the Journal of Geriatric Oncology (JGO) – 6 ANNUAL ISSUES;
- Access the Critical reviews in Oncology/Hematology (CROH) – 12 ANNUAL ISSUES;
- Registration fee discount for the SIOG Annual Conference, SIOG Advanced Courses, SIOG Regional Events and SIOG Preceptorship;
- Vote at the SIOG General Assembly and elect Board members (This applies to standard, emeritus and special membership fees only);
- Participate in Expert Task Forces and Expert Working Group;
- Possibility to become SIOG National Representative;
- Possibility to become SIOG Mentor, member of SIOG Faculty or educational advisor in Geriatric Oncology;
- Possibility to acquire support for Preceptorships in Geriatric Oncology in your country;
- Subscribe to the SIOG Newsletter and keep abreast of the latest developments in the area of geriatric oncology;
- Discounts on selected publications/books (e.g. ESMO Handbook of Geriatric Oncology, and other ESMO Handbooks);
- Networking opportunities to build a strong international coalition in Geriatric Oncology;
- Engage with SIOG activities including its annual conference;
- Represent SIOG at high level meetings in Geriatric Oncology.

BECOME A MEMBER TODAY

More information is available at https://siog.org/about-us/siog-community/join-siog/
The application process for the SIOG 2022 Advanced Course in Treviso, Italy is now open.

Apply today

www.siog.org
#SIOGAdvancedCourse

SIOG 2022 Annual Conference
Geneva, Switzerland
October 28-30, 2022

Mark your Calendars!

Registrations & Abstract Submissions will open in Spring 2022.
www.siogconference.org
SCIENTIFIC & EDUCATIONAL PROJECTS

SIOG TASK FORCES

Older individuals make up a large part of the cancer population, and there are important specific considerations for this population. The SIOG Task Forces assess available evidence on various cancer types in older individuals, and provide evidence-based recommendations for the diagnosis and treatment in such individuals. SIOG Task Forces produce position papers, consensus statements or clinical practice guidelines which then become the official SIOG documents on issues related to cancer in the elderly. Published SIOG Guidelines are available on the following topics:

- Colorectal Cancer in the Elderly
- Prostate Cancer in the Elderly
- Diffuse Large Cell B-Cell Lymphoma
- Cardio toxicity in the Elderly
- Comprehensive Geriatric Assessment
- Radiation Therapy in the Elderly
- Nutrition
- Nursing
- Bladder Cancer in the Elderly

SIOG guidelines on the following topics are currently under development:

- Acute Myeloid Leukemia (AML)
- Corticosteroid therapy in the elderly cancer patient: Expert recommendations from SIOG
- Treatment of ovarian cancer in older adults – Development of treatment algorithms and educational programs
- Update on the management of prostate cancer in older cancer patients
- CGA interventions in older patients with cancer
- Non-melanoma skin cancer in elderly patients
- Management of lung cancer in older patients
- Autologous stem cell transplantation for multiple myeloma patients

SIOG E-LEARNING MODULES

SIOG has developed a series of online educational activities specifically addressing the special considerations that apply to managing the older patient with cancer. These free, continuing education activities aim to identify patient- and disease-related factors that may complicate treatment and share expert perspectives about strategies and tools for providing optimal care for older patient with cancer. Visit www.siog.org for more information

SIOG PRECEPTORSHIP

Designed to give the professionally trained student experience outside the academic environment working with a licensed professional or other advisory.

With the aim of covering the main geriatric oncology issues, the courses are designed primarily for medical and clinical oncologists and aim to educate participants about the current standards of care older adults with cancer. They are particularly suitable for young oncologists and for general oncologists wishing to acquire or update their geriatric oncology knowledge. Each course is accredited by the European Accreditation Council for Continuing Medical Education (EACCME).

The SIOG 2 days Preceptorship courses, which include plenary lectures from a multidisciplinary faculty and case-based discussions, offer a unique learning experience: small size and emphasis on interaction with fellow participants and faculty. Emphasis on interaction and adequate discussion time is provided after all sessions. In order to optimise interaction, participation is limited to about 30 delegates per course. SIOG preceptorships offer:

- A focus on specific geriatric oncology problematics;
- Oncologists with a thorough understanding of the management of the disease in older adults from diagnosis to treatment; according to current standards of care in a multidisciplinary setting;
- An opportunity for participants to expand their professional network as each course is limited to 30 attendees to ensure interaction with participants and faculty members.
SCIENCTIFIC PROGRAMME COMMITTEE

Chairperson & National Convener

Divyanshu Dua (AU)

SIOG President 2020-2022

Ravindran Kanesvaran (SG)

Member

Kwok-Leung Cheung (UK)

Member

Holly Holmes (US)

CME ACCREDITATION

SIOG 2022 Advanced Course in Geriatric Oncology - Virtual from Canberra has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of 14 European CME credits (ECMEC’s). Each medical specialist should claim only those credits that he/she actually spent in the educational activity.

The EACCME® is an institution of the European Union of Medical Specialists (UEMS), www.uems.eu. Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credits to AMA credits can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC® credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
Etienne Brain (FR)

Etienne GC Brain, MD PhD, has been working since 1998 as a medical oncologist at the Hôpital René Huguenin (Saint-Cloud, France), which is now part of the academic centre Institut Curie. He obtained both his MD and PhD from University Paris VII René Descartes, the latter after leading works in preclinical and clinical pharmacology on alkylating agents and liver metabolism in Boston (Dana Farber Cancer Institute and Boston University) and Saint Cloud (Centre René Huguenin). He was the Deputy Director for Research at Centre René Huguenin from 2008-2009, until the merge with Institut Curie happened in 2010. This latter has made the “multisites institution” Institut Curie one of the largest hospitals dedicated to cancer management in Europe, with special focus on breast cancer (~3,000 new cases yearly), employing 2,000 caregivers and 1,000 researchers. Etienne Brain is currently in charge of the settlement of the new Department of Clinical Research of Institut Curie in Saint-Cloud. He is the chairman of the committee for the evaluation of clinical research of the Institut Curie.

Simon Chen (AU)

Simon Chen is a Senior Staff Nurse in the Ambulatory Treatment Unit of the National Cancer Centre Singapore. He completed a one-year program in oncology at University of Melbourne and has obtained Masters of Nursing from National University of Singapore. He is currently a member of nursing and allied health of International Society of Geriatric Oncology (SIOG). As a nurse in Geriatric Oncology multidisciplinary team in NCCS, his interest focuses on optimizing care and management of older patients with cancer by incorporating geriatric nursing concepts into the treatment trajectory. He aims to participate in clinical research encompassing geriatric care models, quality of life and management in this group of patients. In addition, he aims to incorporate evidence-based geri-oncology care, geriatric assessment and patient-centered care combining value driven care framework into the team to improve patients’ quality of life, psychosocial and functional status.

Kwok-Leung Cheung (UK)

Kwok-Leung Cheung is a Professor of Breast Surgery and Medical Education at the University of Nottingham, UK. He qualified and trained at Queen Mary Hospital, Hong Kong. Upon completion of general surgery training, he conducted clinical and laboratory research at the University of Nottingham, UK, with a Doctor of Medicine (in the area of blood tumour markers) awarded in 2001. He was then appointed as Consultant Breast Surgeon at Nottingham University Hospitals where he served as Head of Service, Breast Services (2007 - 2010) and Lead Clinician for Breast Cancer (2007 - 2011). He is currently Consultant Breast Surgeon at University Hospitals of Derby and Burton.

He has obtained surgical fellowship status from Hong Kong, Edinburgh and America. Professor Cheung was selected as one of the 12 International Guest Scholars 2007 of the American College of Surgeons, as a recognition of his strong interests and commitment in teaching and research.

Haryana Dhillon (AU)

Haryana is an Associate Professor in Cancer Survivorship and Psycho-Oncology at the Centre for Medical Psychology and Evidence-based Decision-making (CeMPED) University of Sydney. She is a Director of the Cancer Council NSW Board, and former Member of the Clinical Oncological Society of Australia (COSA) and Council. Haryana is the chair of the Psycho-Oncology Cooperative Research Group’s Scientific Advisory Committee and has leadership roles in supportive care and quality of life in the Australasian Lung Cancer Trials Group and the ANZ Urogenitary and Prostate Cancer Trials Group.

Haryana co-leads a Cancer Survivorship Research Group based in the University of Sydney. The group is supported on peer-reviewed funding allowing studies in cancer and cognition, physical activity in cancer populations, sleep disturbance and symptom control. She also maintains an active research interest in health literacy, communication in the cancer setting and patient education.

Divyanshu Dua (AU)

Dr Divyanshu ‘Divy’ Dua is a consultant medical oncologist and Fellow of the Royal Australasian College of Physicians (RACP). Dr Dua trained in internal medicine and medical oncology in Australia as part of FRACP before completing a clinical fellowship in drug development, early phase trials and thoracic malignancies at the Guy’s Hospital, London (UK), and the Sarah Cannon Research Institute (UK).

Thoracic malignancies – including lung cancer, mesothelioma and thymoma – continue to be of special clinical interest to Dr Dua. He has also published several articles in peer reviewed international journals. He is actively involved in teaching and research through his current affiliation with the Australian National University, Canberra. Past academic affiliations include the University of Adelaide, Flinders University, Monash Rural school of Medicine in Australia and King’s College London. He has also been involved in geriatric oncology services as part of his role as medical oncologist. He has been running the multidisciplinary clinic in Canberra for the past 25 years.

Dr Dua has published several articles in peer reviewed international journals. He is actively involved in teaching and research through his current affiliation with the Australian National University, Canberra. Past academic affiliations include the University of Adelaide, Flinders University, Monash Rural school of Medicine in Australia and King’s College London. He has also been involved in the multidisciplinary clinic in Canberra for the past 25 years.
SPEAKERS

Michelle Hannan (IE)
Michelle Hannan (RGN RNP MSc), is an Advanced Nurse Practitioner in Geriatric Oncology, coordinating the Geriatric Assessment and Liaison clinic within the medical oncology department at University Hospital Waterford, Ireland. Michelle has a specialist interest in the unmet needs of older adults with cancer and developing educational opportunities for oncology nurses.

Holly Holmes (US)
Dr. Holly Holmes is a geriatrician and former pharmacist. She completed a BS in Pharmacy at the University of Texas, Austin, and then received her MD at the University of Texas Health Science Center at Houston (UTHealth). She completed internal medicine residency and geriatrics fellowship at the University of Chicago, where she was subsequently on the geriatrics faculty. She then joined the faculty at Baylor College of Medicine and later took a position as a clinical research faculty member at the University of Texas MD Anderson Cancer Center. Her research and clinical interest focuses on the appropriate use of medications in older patients, particularly those approaching end of life. Her funded research is in pharmacoepidemiology, evaluating claims data for medication use patterns in older patients. She joined the faculty as Director of the Division of Geriatric and Palliative Medicine in September 2015.

Ravindran Kanesvaran (SG)
Assoc Prof Ravindran Kanesvaran is a Senior Consultant and Deputy Head of the Division of Medical Oncology of the National Cancer Centre Singapore and Medical Director of NCCS@SKH Oncology. He is also an Associate Professor at Duke-NUS Medical School and clinical senior lecturer at the Yong Loo Lin School of Medicine, National University of Singapore. He is actively involved in graduate medical education and is the Program Director of the Medical Oncology Senior Residency Program. His research interests include GU oncology and geriatric oncology. He has published in a number of well-known peer reviewed journals including Journal of Clinical Oncology and Lancet Oncology. He is also the author of textbook chapters in the field of geriatric oncology. He has been awarded a number of awards including the American Society of Clinical Oncology (ASCO) GU Merit Award 2009, American Association for Cancer Research (AACR) scholar-in-training Award 2010 and European Society of Medical Oncology (ESMO) fellowship award 2012. He is currently the immediate past President of the Singapore Society of Oncology (SSO) and the Singapore Geriatric Oncology Society. He is a Council Member of ESMO. He is the current President of the International Society of Geriatric Oncology (SIOG). He was the National Representative for Singapore in the International Society of Geriatric Oncology (SIOG) until 2020. He is currently the Vice Chairman of the Singapore Cancer Society (SCS).

Dorothy Keefe (AU)
Professor Keefe is the CEO of Cancer Australia and an honorary Clinical Professor in the School of Medicine at the University of Adelaide. She has had a long career as a Medical Oncologist and Professor of Cancer Medicine. Her areas of expertise include gastrointestinal toxicity of cancer treatment, Supportive Care in Cancer more broadly, Medical Leadership and Health Reform and she has published extensively in the Supportive Care literature. She has a long-standing commitment to the Multinational Association of Supportive Care in Cancer (MASCC), and is a past-president. All her work is focused on improving outcomes for patients.

Heather Lane (AU)
Heather Lane MBChB, FRACP, PhD is a Consultant Geriatrician and Director of Physician Education at Rockingham General Hospital in Western Australia. She holds a Bachelor of Medicine and Surgery from the University of Otago in New Zealand and a doctorate from the Centre for Palliative Care (University of Melbourne and St Vincent’s Hospital (Melbourne). Heather is a member of the Clinical Oncological Society of Australia’s Working Groups for both Geriatric Oncology Research and Guideline Development. She also represents Western Australia as a member of the Royal Australasian College of Physicians Advanced Training Committee for Geriatrician Training and sits on the Geriatric Medicine Education and Training Committee for the Australian and New Zealand Society for Geriatric Medicine. Her research interests include Healthcare Communication, Decision Making, Patient Experience, and Geriatric Assessment in Oncology.

Michelle Hannan (IE)
Michelle Hannan (RGN RNP MSc), is an Advanced Nurse Practitioner in Geriatric Oncology, coordinating the Geriatric Assessment and Liaison clinic within the medical oncology department at University Hospital Waterford, Ireland. Michelle has a specialist interest in the unmet needs of older adults with cancer and developing educational opportunities for oncology nurses.

Holly Holmes (US)
Dr. Holly Holmes is a geriatrician and former pharmacist. She completed a BS in Pharmacy at the University of Texas, Austin, and then received her MD at the University of Texas Health Science Center at Houston (UTHealth). She completed internal medicine residency and geriatrics fellowship at the University of Chicago, where she was subsequently on the geriatrics faculty. She then joined the faculty at Baylor College of Medicine and later took a position as a clinical research faculty member at the University of Texas MD Anderson Cancer Center. Her research and clinical interest focuses on the appropriate use of medications in older patients, particularly those approaching end of life. Her funded research is in pharmacoepidemiology, evaluating claims data for medication use patterns in older patients. She joined the faculty as Director of the Division of Geriatric and Palliative Medicine in September 2015.

Ravindran Kanesvaran (SG)
Assoc Prof Ravindran Kanesvaran is a Senior Consultant and Deputy Head of the Division of Medical Oncology of the National Cancer Centre Singapore and Medical Director of NCCS@SKH Oncology. He is also an Associate Professor at Duke-NUS Medical School and clinical senior lecturer at the Yong Loo Lin School of Medicine, National University of Singapore. He is actively involved in graduate medical education and is the Program Director of the Medical Oncology Senior Residency Program. His research interests include GU oncology and geriatric oncology. He has published in a number of well-known peer reviewed journals including Journal of Clinical Oncology and Lancet Oncology. He is also the author of textbook chapters in the field of geriatric oncology. He has been awarded a number of awards including the American Society of Clinical Oncology (ASCO) GU Merit Award 2009, American Association for Cancer Research (AACR) scholar-in-training Award 2010 and European Society of Medical Oncology (ESMO) fellowship award 2012. He is currently the immediate past President of the Singapore Society of Oncology (SSO) and the Singapore Geriatric Oncology Society. He is a Council Member of ESMO. He is the current President of the International Society of Geriatric Oncology (SIOG). He was the National Representative for Singapore in the International Society of Geriatric Oncology (SIOG) until 2020. He is currently the Vice Chairman of the Singapore Cancer Society (SCS).

Dorothy Keefe (AU)
Professor Keefe is the CEO of Cancer Australia and an honorary Clinical Professor in the School of Medicine at the University of Adelaide. She has had a long career as a Medical Oncologist and Professor of Cancer Medicine. Her areas of expertise include gastrointestinal toxicity of cancer treatment, Supportive Care in Cancer more broadly, Medical Leadership and Health Reform and she has published extensively in the Supportive Care literature. She has a long-standing commitment to the Multinational Association of Supportive Care in Cancer (MASCC), and is a past-president. All her work is focused on improving outcomes for patients.

Heather Lane (AU)
Heather Lane MBChB, FRACP, PhD is a Consultant Geriatrician and Director of Physician Education at Rockingham General Hospital in Western Australia. She holds a Bachelor of Medicine and Surgery from the University of Otago in New Zealand and a doctorate from the Centre for Palliative Care (University of Melbourne and St Vincent’s Hospital (Melbourne). Heather is a member of the Clinical Oncological Society of Australia’s Working Groups for both Geriatric Oncology Research and Guideline Development. She also represents Western Australia as a member of the Royal Australasian College of Physicians Advanced Training Committee for Geriatrician Training and sits on the Geriatric Medicine Education and Training Committee for the Australian and New Zealand Society for Geriatric Medicine. Her research interests include Healthcare Communication, Decision Making, Patient Experience, and Geriatric Assessment in Oncology.
**Speakers**

**Catherine Paterson (AU)**

Dr. Catherine Paterson is an Associate Professor of Nursing, Faculty of Health, University of Canberra. Catherine completed her Ph.D. in 2013 and holds the following educational qualifications from the UK all with Distinctions (BA, MSc, non-medical prescribing, PGCert, LTA, FHEA). Catherine is a registered nurse in Australia (APRHA) and in the UK (NMC). She holds a visiting appointment with ACT Health, Canberra Cancer Hospital and is honorary senior lecturer at Robert Gordon University, Aberdeen, UK.

Catherine conducts research in all areas of urology, and uro-oncology. She has expertise in conducting systematic reviews, ecological momentary assessment methodology, mixed methods, and complex interventions. She has experience of working in health services research for over 15 years. Catherine has published widely and supervises HDR students.

**Ganes Pranavan (AU)**

Dr. Ganes Pranavan is a consultant medical oncologist at the Canberra Hospital with subspecialty interest in geriatric oncology, genito-urinary malignancies and neuro-oncology. Dr Pranavan has been working as a staff specialist in The Canberra Hospital since 2009. He is the principal investigator of several clinical trials in the above subspecialties at The Canberra Hospital. Dr Pranavan has been actively involved with the geriatric oncology multidisciplinary clinics in the Canberra Hospital since 2017. He serves as a lecturer at the Australian National University and has been involved with core teaching activities of the ANU medical school. He is also an active member of various national and international cancer organisations.

**Tanujaa Rajasekaran (SG)**

Dr. Tanujaa Rajasekaran is a Consultant in the Department of Medical Oncology of the National Cancer Centre Singapore, subspecializing in genitourinary, thoracic and head and neck cancers. She graduated from the National University of Singapore and was awarded the Dean’s list during her undergraduate studies. She completed her medical oncology specialty training in the National Cancer Centre Singapore. Her research interests are in geriatric oncology and genitourinary cancers. She also awarded the European Society of Medical Oncology (ESMO) fellowship grant in 2013 for her research in geriatric oncology. She has published in a number of well-known peer reviewed journals including Journal of Clinical Oncology.

She is also actively involved in medical education. She is a core faculty member of the Medical Oncology Senior Residency Program and Clinical Lecturer in Yong Loo Lin School of Medicine, NUS.

**Angela Rezo (AU)**

Dr. Angela Rezo is a radiation oncologist with 20 years of experience who is committed to delivering high quality modern cancer treatment and developing a strong therapeutic relationship with her patients. She is an active member of the breast, brain, and lung cancer multi-disciplinary teams in the ACT, and is a clinical leader for the stereotactic service at the Canberra Hospital. Dr Rezo strives to ensure patients receive individualised treatment recommendations according to the most up-to-date evidence.

**Anupama Roy Chowdhury (SG)**

Dr. Anupama Roy Chowdhury is a Senior Consultant with Sengkang General Hospital. She received her medical degree from the National University of Singapore in 2002. She completed her specialist training in geriatric medicine in 2010 and went on to do a fellowship in dementia and neurocognitive disorders at the University of British Columbia, Vancouver in 2013. She has a special interest in dementia, geriatric oncology and medical education. She has previously been secretary and then vice-president of Society of Geriatric Medicine Singapore (SGMS).

**Mary Salazar (US)**

Mary Salazar is a Nurse Practitioner with a Doctorate in Nursing Practice. She is employed by the University of Texas Mays Cancer Center in San Antonio, Texas. Her current title is Director of the Oncology Patient Experience. Her clinical focus is hepatobiliary / pancreatic solid tumors. She is also an Assistant Professor in the School of Nursing and the Long School of Medicine at the University of Texas Health Science Center San Antonio.
**Pierre Soubeyran (FR)**

Pierre Soubeyran, M.D., Ph.D., is a Medical Oncologist at Institut Bergonié, Comprehensive Cancer Center in Bordeaux, and Professor of Medical Oncology at the University of Bordeaux. He is highly involved in the development of Geriatric Oncology at both the clinical (co-coordinator of the Coordination Unit of Geriatric Oncology of Aquitaine) and research level (President of the Scientific Council of the French Society of Geriatric Oncology (SoFOG) and Coordinator of the French Geriatric Oncology Cooperative Group DIALOG). He is also involved in cancer research as Director of the U1218 INSERM Cancer research unit and Director of the IRIS Center for Integrated Cancer Research of Bordeaux, named BRIO (Bordeaux Recherche Intégrée Oncologie). He earned his Medical Degree from the University of Nantes in France and trained in Medical Oncology at the Institut Bergonié and University of Bordeaux. He completed a fellowship at the MD Anderson Cancer Center in Houston and later obtained his Ph.D. at the University of Bordeaux in the field of minimal residual disease in follicular lymphoma. An active researcher, Prof. Pierre Soubeyran’s clinical interests include clinical and biological research on lymphoma and geriatric oncology. He is leading trials focused on these topics as part of the French LYSAN lymphoma Research Group and the French Geriatric Oncology Cooperative Group DIALOG. He is a member of ESMO, ASCO, ASH, SoFOG and SIOG. He has authored and co-authored numerous articles, book chapters and monographs on various aspects of cancer treatment.

---

**Christopher Steer (AU)**

Dr Steer is a medical oncologist working at Border Medical Oncology in the recently completed Albury Wodonga Regional Cancer Centre. He developed an interest in the care of older adults with cancer during his 3-year clinical research fellowship at Guy’s Hospital in London. He returned to private practice in Albury in 2003. Christopher was the inaugural chair of the geriatric oncology interest group of the Clinical Oncological Society of Australia (COSA). He is actively involved in the International Society of Geriatric Oncology (SIOG) and was chair of the scientific committee of the annual scientific meeting in Prague in November 2015. He is an editorial board member of the Journal of Geriatric Oncology and the European Journal of Surgical Oncology. Christopher is chair of the geriatric oncology interest group of the Multinational Association for Supportive Care in Cancer (MASCC). Christopher is the current president of the Private Cancer Physicians of Australia (PCPA) and is a member of the MOGA/PCPA cancer drugs working group. Christopher is a principal investigator at the Border Medical Oncology research unit (BMORU). The BMORU has been recognized for innovation in clinical research particularly in delivering care to a rural/regional population. Christopher has led a pilot project of supportive care in older adults with cancer with funding from Cancer Australia.

---

**Farhan Syed (AU)**

Dr Farhan Syed is a Radiation Oncologist at Canberra Health Services with special interest in stereotactic radiotherapy, urological and gastrointestinal malignancies. He is the Australian Capital Territory’s Clinical Lead and Steering Committee Member for the Prostate Cancer Outcome Registry – Australia and New Zealand. He is also the Director of Training for accredited radiation oncology registrars at the Canberra Hospital. He is the local principal investigator for multiple local and cooperative clinical trials. He investigates immunomodulatory effects of cancer and radiotherapy in pre-clinical studies at the Irradiation Immunity Interaction Laboratory at John Curtin School of Medical Research, Australian National University.

---

**Kok-Yang Tan (SG)**

He specializes in colorectal cancer surgery and laparoscopic colorectal surgery with a special interest in low rectal cancers and sphincter-preserving surgery. He is also trained to perform advanced procedures in colonoscopy. His research work is well published in numerous international peer-reviewed journals. He is on the International Advisory Board of Digestive Endoscopy and also on the Editorial Boards of European Journal of Surgical Oncology, World Journal of Gastroenterology and World Journal of Gastrointestinal Endoscopy. He has also written a number of book chapters on colorectal surgery and published a number of editorials in international surgical journals. He is the editor of the books "Colorectal Cancer in the Elderly" and "Transdisciplinary Perioperative Care in Colorectal Surgery" published by Springer in 2012 and 2014 respectively. He is a member of the Surgical Residency Advisory Committee of Singapore and has also been appointed as National Examiner for General Surgery. He is also a member of the Singapore Medical Council Complaints Panel and serves on the Committee of the National Advisory Committee for Cancer. He served as the President of the Society of Colorectal Surgeons of Singapore from 2015 to 2017. He also served as a Board Member of the Chapter of General Surgeons of the College of Surgeons. His other passion in the field of surgery is the improvement of outcomes in elderly patients. He is the Clinical Director of the Geriatric Surgery Programme of Khoo Teck Puat Hospital. He is actively involved in projects and clinical research on this challenging group of patients and is a member of the American Geriatrics Society and founded The Geriatric Surgery Society of Singapore in 2017.
SCIENTIFIC PROGRAMME

DAY 1 - January 22, 2022
Important: times are expressed based on Canberra time zone

08:30 - 09:40 OPENING SESSION
Chair: Divyanshu Dua (AU)
Welcoming remarks: Divyanshu Dua (AU)
Keynote Address: Prof. Dorothy Keefe, CEO Cancer Australia
Course History & Introduction: Challenges in Geriatric Oncology: Etienne Brain (FR)

09:40 - 10:00 BREAK

10:00 - 10:35 BIOLOGY OF AGING
Holly Holmes (US)
10:35 - 11:10 GERIATRIC ASSESSMENT
Anupama Roy Chowdhury (SG)
11:10 - 11:45 MAJOR GERIATRIC SYNDROMES
Holly Holmes (US)
11:45 - 12:10 FRAILTY
Anupama Roy Chowdhury (SG)
12:10 - 12:30 Q&A

12:30 - 13:30 BREAK

13:30 - 14:10 GERIATRIC ONCOLOGY: MEDICAL ONCOLOGY PERSPECTIVE AND RECENT ADVANCES
Christopher Steer (AU)
14:10 - 14:50 NUTRITION & BONE HEALTH ISSUES IN OLDER ADULTS
Divyanshu Dua (AU)
14:50 - 15:15 PRE-HABILITATION AND ITS ROLE IN GERIATRIC ONCOLOGY: A SURGEON’S PERSPECTIVE
Kwok Leung Cheung (UK)
15:15 - 15:30 Q&A

15:30 - 16:00 BREAK

16:00 - 16:30 PREDICTION OF TOXICITY OF CHEMOTHERAPY IN OLDER PATIENTS AND INTEGRATION IN DAY-TO-DAY PRACTICE
Tanujaa Rajasekaran (SG)
16:30 - 16:35 Q&A

16:35 - 17:35 GERIATRIC ONCOLOGY AND HAEMATOLOGY
Pierre Soubeyran (FR)
17:35 - 17:50 Q&A
SCIENTIFIC PROGRAMME

DAY 2 - January 23, 2022

Important: times are expressed based on Canberra time zone

08:30 – 10:00 MULTI-DISCIPLINARY TEAM CASE STUDY: EARLY & METASTATIC BREAST CANCER
Chair: Etienne Brain (FR)
Medical Oncology Perspective: Etienne Brain (FR)
Radiation Oncology Perspective: Angela Rezo (AU)
Surgical Perspective: Kwok Leung Cheung (UK)
Geriatrics Perspective: Anupama Roy Chowdhury (SG)
Nursing Perspective: Michelle Hannan (IE)

10:00 – 10:30 BREAK

10:30 – 12:00 MULTI-DISCIPLINARY TEAM CASE STUDY: EARLY & METASTATIC LUNG CANCER
Chair: Ravindran Kanesvaran (SG)
Medical Oncology Perspective: Ravindran Kanesvaran (SG)
Radiation Oncology Perspective: Angela Rezo (AU)
Psychology Perspective: Haryana Dhillon (AU)
Geriatrics Perspective: Holly Holmes (US)
Nursing Perspective: Simon Chen (SG)

12:00 – 13:00 AUSTRALIAN GERIATRIC ONCOLOGY UPDATE
Divyanshu Dua (AU)

13:00 – 14:00 BREAK

14:00 – 15:30 MULTI-DISCIPLINARY TEAM CASE STUDY: EARLY & METASTATIC GENITOURINARY CANCER
Chair: Ganes Pranavan (AU)
Medical Oncology Perspective: Ganes Pranavan (AU)
Radiation Oncology Perspective: Farhan Syed (AU)
Psychology Perspective: Haryana Dhillon (AU)
Geriatrics Perspective: Heather Lane (AU)
Nursing Perspective: Catherine Paterson (AU)

15:30 – 16:00 BREAK

16:00 – 17:30 MULTI-DISCIPLINARY TEAM CASE STUDY: EARLY & METASTATIC COLORECTAL CANCER
Chair: Christopher Steer (AU)
Medical Oncology Perspective: Christopher Steer (AU)
Radiation Oncology Perspective: Farhan Syed (AU)
Surgical Perspective: Kok-Yang Tan (SG)
Geriatrics Perspective: Anupama Roy Chowdhury (SG)
Nursing Perspective: Mary Salazar (US)

17:30 – 18:00 CONCLUDING REMARKS
The following industry sponsored satellite session is being organised by AstraZeneca.

Saturday 22nd January 2022

MANAGEMENT OF FRAILTY IN OLDER ADULTS WITH LUNG CANCER
Chair: Bernadine Bishop (AU)

12:40 - Welcome
12:45 - Management of Frailty in Older Adults with Lung Cancer
James Fletcher (AU)
13:15 - Q&A
13:25 - Close
SIOG gratefully acknowledges the generous contribution the following companies have made to SIOG Advanced Course in Geriatric Oncology - Canberra.

**ASTRA ZENECA**

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory & Autoimmunity, Cardiovascular & Metabolic Disease and Oncology. The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit: https://www.astrazeneca.com.au/

**BRISTOL MEYERS SQUIBB**

Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients’ lives through science.

https://www.bms.com/au
https://twitter.com/bmsnews
https://www.linkedin.com/company/bristol-myers-squibb/
https://www.instagram.com/bristolmyerssquibb/
https://www.facebook.com/BristolMyersSquibb

**IPSEN**

Ipsen provides specialty medicines and quality services to healthcare professionals and their patients suffering from debilitating diseases.

At Ipsen, our passion is improving the lives of patients. We do this by working together to build partnerships based on trust and mutual respect with Healthcare Professionals. We deliver tailored solutions through our agility and innovation and we strive to be even better tomorrow than we are today.

Ipsen Pty Ltd is the Australian affiliate of a global biotech company. Please see the website below for details of Ipsen's presence in Australia:

https://www.ipsen.com/aus/

**PFIZER**

One way or another, cancer touches all our lives. Which is why nothing is more personal, or more urgent, than our goal to find cures for cancer. This motivates all of us at Pfizer, and we share that goal with healthcare providers, patient advocates, caregivers, biopharma companies, and everyone living with cancer.

Together, we’ve made meaningful progress, but our work is far from finished. The millions of people living with cancer and the millions more who will receive a diagnosis are the reason we continue to work relentlessly to deliver on our purpose: breakthroughs that change patients’ lives.

If you would like to submit a medical enquiry regarding a Pfizer product, please visit www pfizermedicalinformation.com.au

If you need to report an adverse event for a Pfizer medicine, please contact Pfizer Drug Safety at AUS.AEReporting@pfizer.com


https://www.instagram.com/pfizeraustralia/
The Medical Oncology Group of Australia Incorporated (MOGA) is the national, professional organisation for medical oncologists and the profession in Australia. As a Specialty Society of the Royal Australasian College of Physicians, MOGA maintains strong strategic alliances, working in close collaboration with many professional organisations and agencies in Australia and overseas. We work closely with Government, health organisations, affiliated international associations and societies, industry and learned Colleges to improve and develop the profession of medical oncology and the management of cancer both nationally and globally.

ACKNOWLEDGEMENT

SIOG would like to acknowledge our corporate financial sponsors for their generous contribution and support and we look forward to a lasting partnership. We also wish to extend our special thanks to the SIOG 2022 Canberra Scientific Programme Committee for their contribution to the programme of the SIOG Advanced Course. A special acknowledgment to the supporting organisation. Our gratitude to all the speakers for their patience and continued support.

We also thank in particular our course attendees for their cooperation in attending the second virtual SIOG Advanced Course.

This edition of SIOG 2022 Advanced Course in Geriatric Oncology has welcomed participants from many countries and has constituted our first memorable event of 2022.

Thank you everyone for helping us deliver SIOG 2022 Advanced Course in Geriatric Oncology Virtual from Canberra.

SIOG Head Office